Email updates

Keep up to date with the latest news and content from The EPMA Journal and BioMed Central.

Open Access Review

Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Anja Mähler12*, Silvia Mandel3, Mario Lorenz4, Urs Ruegg5, Erich E Wanker6, Michael Boschmann1 and Friedemann Paul12

Author Affiliations

1 Experimental and Clinical Research Center, a joint cooperation between the Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, D-13125, Germany

2 NeuroCure Clinical Research Center, Charité University Medicine, Berlin, D-10117, Germany

3 Department of Molecular Pharmacology, Faculty of Medicine, Eve Topf Center of Excellence for Neurodegenerative Diseases Research and Department of Molecular Pharmacology, Faculty of Medicine, Technion, Haifa, 31905, Israel

4 Medizinische Klinik für Kardiologie und Angiologie, Charité University Medicine Berlin, Campus Mitte, Berlin, D-10117, Germany

5 Geneva-Lausanne School of Pharmaceutical Sciences, University of Geneva, Geneva, CH-1211, Switzerland

6 Department of Proteomics and Molecular Mechanisms of Neurodegenerative Diseases, Max Delbrueck Center for Molecular Medicine, Berlin, D-13125, Germany

For all author emails, please log on.

EPMA Journal 2013, 4:5  doi:10.1186/1878-5085-4-5

Published: 18 February 2013

Abstract

Neurodegenerative disorders show an increasing prevalence in a number of highly developed countries. Often, these diseases require life-long treatment mostly with drugs which are costly and mostly accompanied by more or less serious side-effects. Their heterogeneous manifestation, severity and outcome pose the need for individualised treatment options. There is an intensive search for new strategies not only for treating but also for preventing these diseases. Green tea and green tea extracts seem to be such a promising and safe alternative. However, data regarding the beneficial effects and possible underlying mechanism, specifically in clinical trials, are rare and rather controversial or non-conclusive. This review outlines the existing evidence from preclinical studies (cell and tissue cultures and animal models) and clinical trials regarding preventive and therapeutic effects of epigallcatechin-3-gallate in neurodegenerative diseases and considers antioxidative vs. pro-oxidative properties of the tea catechin important for dosage recommendations.

Keywords:
Neurological diseases; Predictive and personalised medicine; Targeted prevention; Green tea; Epigallocatechin-3-gallate; Tailored therapy